Asia Pacific Botulinum Toxin Market Forecast to 2031

At 14.6% CAGR, Asia Pacific Botulinum Toxin Market is Speculated to be Worth US$ 2,743.18 Million by 2031, says The Research Team

According to The Research Team’ research, the Asia Pacific botulinum toxin market was valued at US$ 925.29 million in 2023 and is expected to reach US$ 2,743.18 million by 2031, registering a CAGR of 14.6% from 2023 to 2031. Rising adoption aesthetic procedure in emerging economies is offering significant and increasing use of botulinum toxin for enhancing facial aesthetics are among the critical factors attributed to drive the Asia Pacific botulinum toxin market growth.

Healthcare providers in developing economies are focusing on introducing various advanced medical aesthetic technologies into their service portfolios. Health facilities, medical spas, and wellness centers in these countries also offer a comprehensive range of inexpensive but high-quality medical-aesthetic procedures. Patients from developed regions approach emerging countries to undergo various aesthetic procedures. Moreover, people in these countries are willing to spend on cosmetic and rejuvenation procedures to improve aesthetics. Rising disposable income and changing beauty standards have led to an increase in demand for botulinum toxin and similar products in the abovementioned region. Moreover, the botulinum toxin industry is flourishing in India as people seek nonsurgical cosmetic alternatives to invasive procedures. Further, countries in Asia Pacific and Latin America are catching up to the botulinum toxin market in Brazil, Argentina, India, and Thailand usage due to urbanization and increased healthcare spending. Rising healthcare spending in developing economies in Asia Pacific, and South & Central America enables healthcare professionals to adopt advanced technologies for performing cosmetic procedures. For instance, according to the ISAPS, in 2021 the number of non-surgical procedures in Brazil, Argentina, India and Thailand was 542,520; 158,900; 404,016; and 29,840 respectively. Thus, evolving consumer preferences, and growing awareness, developing countries offer significant opportunities for the botulinum toxin market.

On the contrary, side effects of botulinum toxin hamper the growth of Asia Pacific botulinum toxin market.

Based on product, the Asia Pacific botulinum toxin market is bifurcated into botulinum toxin A and botulinum toxin B. The botulinum toxin A segment held 95.1% share of Asia Pacific botulinum toxin market share in 2023, amassing US$ 879.91 million. It is projected to garner US$ 2,643.62 million by 2031 to register 14.7% CAGR during 2023–2031.

In terms of application, the Asia Pacific botulinum toxin market is bifurcated into medical and aesthetic. The medical segment held 59.3% share of Asia Pacific botulinum toxin market in 2023, amassing US$ 549.10 million. It is anticipated to garner US$ 1,712.50 million by 2031 to expand at 15.3% CAGR during 2023–2031. Furthermore, the medical segment is subcategorized into chronic migraine, muscle spasm, over reactive bladder, hyperhidrosis, and others. Additionally, the aesthetic segment is subcategorized into frown lines/ glabellar, forehead lines, crow’s feet, square jaw/ masseter, and others.

By end user, the Asia Pacific botulinum toxin market is divided into specialty & dermatology clinics, hospitals & clinics, and others. The specialty and dermatology clinics segment held 52.9% share of Asia Pacific botulinum toxin market in 2023, amassing US$ 489.38 million. It is projected to garner US$ 1,531.53 million by 2031 to expand at 15.3% CAGR from 2023 to 2031.

Based on country, the Asia Pacific botulinum toxin market is categorized into Japan, China, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that Japan captured 34.4% share of Asia Pacific botulinum toxin market in 2023. It was assessed at US$ 318.21 million in 2023 and is likely to hit US$ 954.98 million by 2031, registering a CAGR of 14.7% during 2023–2031.

Key players operating in the Asia Pacific botulinum toxin market are Merz Pharma GmbH & Co KGaA, AbbVie Inc, Ipsen SA, Evolus Inc, Medytox Inc, Galderma SA, Hugel Inc, and Lanzhou Institute of Biological Products Co Ltd , among others.

In February-2022, Merz Therapeutics is expanding its strategic partnership with Vensica Therapeutics as the Merz Group invests up to US$3 million in the Israeli start-up. This investment follows the strategic license and collaboration agreement signed in 2021 to utilize Merz’s botulinum neurotoxin A (XEOMIN) for the innovative ultrasound-assisted delivery catheter of Vensica. Merz is thus executing its contractually agreed option to participate in Vensica’s Series C financing round and invest further in the start-up.
In August-2021, Merz Therapeutics and the Israeli start-up Vensica Therapeutics Ltd., a urology company, announced that they have entered into a strategic license and collaboration agreement to deliver botulinum neurotoxin A (XEOMIN)to the bladder wall by using Vensica’s innovative ultrasound-assisted delivery catheter. By this, Merz Therapeutics becomes the exclusive toxin supplier of any needleless application for urological indications, such as overactive bladder, neurogenic bladder, interstitial cystitis, and other urology indications.
In June-2020, Merz Therapeutics GmbH and Teijin Pharma Limited jointly announced that Teijin Pharma had been approved by Japan’s Ministry of Health, Labor and Welfare (MHLW) to market XEOMIN (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of upper limb spasticity. XEOMIN is effective in treating peripheral cholinergic nerve endings by weakening the contraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of a neurotransmitter called acetylcholine.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific botulinum toxin market.
o Highlights key business priorities in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific botulinum toxin market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific botulinum toxin market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Botulinum Toxin Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Popularity of Noninvasive Aesthetics Procedures
4.1.2 Increasing Use of Botulinum Toxin for Enhancing Facial Aesthetics
4.2 Market Restraints
4.2.1 Side Effects of Botulinum Toxin
4.3 Market Opportunities
4.3.1 Rising Adoption of Aesthetic Procedure in Emerging Economies
4.4 Future Trends
4.4.1 Expanding Therapeutic Applications
4.5 Impact of Drivers and Restraints:
5. Botulinum Toxin Market – Asia Pacific Analysis
5.1 Overview
5.2 Botulinum Toxin Market Revenue (US$ Million), 2021–2031
6. Asia Pacific Botulinum Toxin Market Analysis – by Product
6.1 Overview
6.2 Botulinum Toxin A
6.2.1 Overview
6.2.2 Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
6.3 Botulinum Toxin B
6.3.1 Overview
6.3.2 Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7. Asia Pacific Botulinum Toxin Market Analysis – by Application
7.1 Overview
7.2 Medical
7.2.1 Overview
7.2.2 Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.2.2.1 Asia Pacific Botulinum Toxin Market Breakdown, by Medical
7.3 Aesthetic
7.3.1 Overview
7.3.2 Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
7.3.2.1 Asia Pacific Botulinum Toxin Market Breakdown, by Aesthetic
8. Asia Pacific Botulinum Toxin Market Analysis – by End User
8.1 Overview
8.2 Specialty and Dermatology Clinics
8.2.1 Overview
8.2.2 Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.3 Hospitals and Clinics
8.3.1 Overview
8.3.2 Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9. Asia Pacific Botulinum Toxin Market – Country Analysis
9.1 Asia Pacific: Botulinum Toxin Market
9.1.1 Asia Pacific: Botulinum Toxin Market – Revenue and Forecast Analysis – by Country
9.1.1.1 Japan
9.1.1.1.1 Overview
9.1.1.1.2 Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.1.3 Japan: Botulinum Toxin Market Breakdown, by Product
9.1.1.1.4 Japan: Botulinum Toxin Market Breakdown, by Application
9.1.1.1.4.1 Japan: Botulinum Toxin Market Breakdown, by Medical
9.1.1.1.4.2 Japan: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.1.5 Japan: Botulinum Toxin Market Breakdown, by End User
9.1.1.2 China
9.1.1.2.1 Overview
9.1.1.2.2 China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.2.3 China: Botulinum Toxin Market Breakdown, by Product
9.1.1.2.4 China: Botulinum Toxin Market Breakdown, by Application
9.1.1.2.4.1 China: Botulinum Toxin Market Breakdown, by Medical
9.1.1.2.4.2 China: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.2.5 China: Botulinum Toxin Market Breakdown, by End User
9.1.1.3 India: Botulinum Toxin Market – Revenue and Forecast to 2030 (US$ Million)
9.1.1.3.1 Overview
9.1.1.3.2 India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.3.3 India: Botulinum Toxin Market Breakdown, by Product
9.1.1.3.4 India: Botulinum Toxin Market Breakdown, by Application
9.1.1.3.4.1 India: Botulinum Toxin Market Breakdown, by Medical
9.1.1.3.4.2 India: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.3.5 India: Botulinum Toxin Market Breakdown, by End User
9.1.1.4 South Korea
9.1.1.4.1 Overview
9.1.1.4.2 South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.4.3 South Korea: Botulinum Toxin Market Breakdown, by Product
9.1.1.4.4 South Korea: Botulinum Toxin Market Breakdown, by Application
9.1.1.4.4.1 South Korea: Botulinum Toxin Market Breakdown, by Medical
9.1.1.4.4.2 South Korea: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.4.5 South Korea: Botulinum Toxin Market Breakdown, by End User
9.1.1.5 Australia
9.1.1.5.1 Overview
9.1.1.5.2 Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.5.3 Australia: Botulinum Toxin Market Breakdown, by Product
9.1.1.5.4 Australia: Botulinum Toxin Market Breakdown, by Application
9.1.1.5.4.1 Australia: Botulinum Toxin Market Breakdown, by Medical
9.1.1.5.4.2 Australia: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.5.5 Australia: Botulinum Toxin Market Breakdown, by End User
9.1.1.6 Rest of Asia Pacific
9.1.1.6.1 Overview
9.1.1.6.2 Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
9.1.1.6.3 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Product
9.1.1.6.4 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Application
9.1.1.6.4.1 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Medical
9.1.1.6.4.2 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by Aesthetic
9.1.1.6.5 Rest of Asia Pacific: Botulinum Toxin Market Breakdown, by End User
10. Company Profiles
10.1 Merz Pharma GmbH & Co KGaA
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 AbbVie Inc
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Ipsen SA
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Evolus Inc
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 Medytox Inc
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Galderma SA
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Hugel Inc
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Lanzhou Institute of Biological Products Co Ltd
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
11. Appendix
11.1 About The Research Team
11.2 Glossary of Terms

LIST OF TABLES

Table 1. Botulinum Toxin Market Segmentation
Table 2. Asia Pacific Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 3. Asia Pacific Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 4. Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 5. Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 6. Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 7. Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 8. Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 9. China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 10. China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 11. China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 12. China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 13. China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 14. India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 15. India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 16. India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 17. India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 18. India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 19. South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 20. South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 21. South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 22. South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 23. South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 24. Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 25. Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 26. Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 27. Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 28. Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 29. Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Product
Table 30. Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Application
Table 31. Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Medical
Table 32. Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by Aesthetic
Table 33. Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million) – by End User
Table 34. Glossary of Terms

LIST OF FIGURES

Figure 1. Botulinum Toxin Market Segmentation, by Country
Figure 2. Botulinum Toxin Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Botulinum Toxin Market Revenue (US$ Million), 2021–2031
Figure 5. Botulinum Toxin Market Share (%) – by Product (2023 and 2031)
Figure 6. Botulinum Toxin A: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 7. Botulinum Toxin B: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 8. Botulinum Toxin Market Share (%) – by Application (2023 and 2031)
Figure 9. Medical: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 10. Aesthetic: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 11. Botulinum Toxin Market Share (%) – by End User (2023 and 2031)
Figure 12. Specialty and Dermatology Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 13. Hospitals and Clinics: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 15. Asia Pacific: Botulinum Toxin Market, by Key Country – Revenue (2023) (US$ Million)
Figure 16. Asia Pacific: Botulinum Toxin Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 17. Japan: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 18. China: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 19. India: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 20. South Korea: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 21. Australia: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)
Figure 22. Rest of Asia Pacific: Botulinum Toxin Market – Revenue and Forecast to 2031 (US$ Million)